Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders

Schizophrenia Research and Treatment

Volumn 2016, Issue , 2016, Pages

  Lee, Hyeong Min ^a   Kim, Yuna ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPHOTERICIN B; ARBACLOFEN; ATOMOXETINE; CLOZAPINE; DEXMECAMYLAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOTAMINE TARTRATE; FENFLURAMINE; FLUOXETINE; GALANTAMINE; MECAMYLAMINE; METHYSERGIDE MALEATE; MIFEPRISTONE; NEUROLEPTIC AGENT; NORFENFLURAMINE; NORFLUOXETINE; OLANZAPINE; PHENTERMINE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 2A ANTAGONIST; SERTRALINE; UNINDEXED DRUG; VENLAFAXINE; ZIMELDINE;

ANXIETY DISORDER; DEPRESSION; DRUG COST; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG REPOSITIONING; DRUG TARGETING; HEADACHE; HUMAN; INSOMNIA; MENTAL DISEASE; MIGRAINE; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT;

EID: 85034019284     PISSN: 20902085     EISSN: 20902093     Source Type: Journal    
DOI: 10.1155/2016/6378137     Document Type: Review

References (140)

1. M. T. Bianchi, "Non-serotonin anti-depressant actions: direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy, " Medical Hypotheses, vol. 70, no. 5, pp. 951-956, 2008.
2. G. Rammes and R. Rupprecht, "Modulation of ligand-gated ion channels by antidepressants and antipsychotics, " Molecular Neurobiology, vol. 35, no. 2, pp. 160-174, 2007.
3. M. T. Bianchi, "Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications, " Medical Hypotheses, vol. 74, no. 2, pp. 297-300, 2010.
4. H. Y. Zhang and X. C. Tang, "Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease, " Trends in Pharmacological Sciences, vol. 27, no. 12, pp. 619-625, 2006.
5. E. E. Benarroch, "Tissue plasminogenactivator: beyond thrombolysis, " Neurology, vol. 69, no. 8, pp. 799-802, 2007.
6. N. Crosby, K. H. Deane, and C. E. Clarke, "Amantadine in Parkinson's disease, " Cochrane Database of Systematic Reviews, no. 1, Article IDCD003468, 2003.
7. R. S. Schwab, A. C. England Jr., D. C. Poskanzer, and R. R. Young, "Amantadine in the treatment of Parkinson's disease, " The Journal of the American Medical Association, vol. 208, no. 7, pp. 1168-1170, 1969.
8. H. Mitsuya, K. J. Weinhold, P. A. Furman et al., "3-Azido-3-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro, " Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 20, pp. 7096-7100, 1985.
9. R. Sun, S. Eriksson, and L. Wang, "Identification and characterization of mitochondrial factors modulating thymidine kinase 2 activity, " Nucleosides, Nucleotides & Nucleic Acids, vol. 29, no. 4-6, pp. 382-385, 2010.
10. R. Yarchoan, R. W. Klecker, K. J. Weinhold et al., "Administration of 3-azido-3-deoxythymidine, an inhibitor of HTLVIII/ LAV replication, to patients with AIDS or AIDS-related complex, " The Lancet, vol. 1, no. 8481, pp. 575-580, 1986.
11. R. F. DeBusk, C. J. Pepine, D. B. Glasser, A. Shpilsky, H. DeRiesthal, and M. Sweeney, "Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease, "The American Journal of Cardiology, vol. 93, no. 2, pp. 147-153, 2004.
12. W. K. Kroeze and B. L. Roth, "Polypharmacological drugs: "magic shotguns" for psychiatric diseases, " in Polypharmacology in Drug Discovery, J.-U. Peters, Ed., pp. 135-148, JohnWiley & Sons, Somerset, NJ, USA, 2012.
13. T. T. Ashburn and K. B. Thor, "Drug repositioning: identifying and developing new uses for existing drugs, " Nature Reviews: Drug Discovery, vol. 3, no. 8, pp. 673-683, 2004.
14. A. L. Hopkins, "Drug discovery: predicting promiscuity, " Nature, vol. 462, no. 7270, pp. 167-168, 2009.
15. K. Marusina, D. J. Welsch, L. Rose, D. Brock, and N. Bahr, "The CTSA Pharmaceutical Assets Portal-a public-private partnership model for drug repositioning, " Drug Discovery Today:Therapeutic Strategies, vol. 8, no. 3-4, pp. 77-83, 2011.
16. K. A. O'Connor and B. L. Roth, "Finding new tricks for old drugs: An efficient route for public-sector drug discovery, " Nature Reviews Drug Discovery, vol. 4, no. 12, pp. 1005-1014, 2005.
17. T. I. Oprea, J. E. Bauman, C. G. Bologa et al., "Drug repurposing from an academic perspective, " Drug Discovery Today. Therapeutic Strategies, vol. 8, no. 3-4, pp. 61-69, 2011.
18. P. J. Harrison and M. J. Owen, "Genes for schizophrenia? Recent findings and their pathophysiological implications, " The Lancet, vol. 361, no. 9355, pp. 417-419, 2003.
19. C. M. Lewis, D. F. Levinson, L. H. Wise et al., "Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia, " American Journal of Human Genetics, vol. 73, no. 1, pp. 34-48, 2003.
20. J. T. Coyle and R. S. Duman, "Finding the intracellular signaling pathways affected by mood disorder treatments, " Neuron, vol. 38, no. 2, pp. 157-160, 2003.
21. B. L. Roth, D. Sheffler, and S. G. Potkin, "Atypical antipsychotic drug actions: unitary ormultiple mechanisms for 'atypicality'?" Clinical Neuroscience Research, vol. 3, no. 1-2, pp. 108-117, 2003.
22. V. Setola and B. L. Roth, "Why mice are neither miniature humans nor small rats: A cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants, " Molecular Pharmacology, vol. 64, no. 6, pp. 1277-1278, 2003.
23. E. Shorter, "Looking backwards: A possible new path for drug discovery in psychopharmacology, " Nature Reviews Drug Discovery, vol. 1, no. 12, pp. 1003-1006, 2002.
24. A. Carlsson and D. T. Wong, "A note on the discovery of selective serotonin reuptake inhibitors, " Life Sciences, vol. 61, no. 12, p. 1203, 1997.
25. D. T. Wong, F. P. Bymaster, and E. A. Engleman, "Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication, " Life Sciences, vol. 57, no. 5, pp. 411-441, 1995.
26. H. Hippius, "A historical perspective of clozapine, " The Journal of Clinical Psychiatry, vol. 60, supplement 12, pp. 22-23, 1999.
27. P. J. Conn and B. L. Roth, "Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings, " Neuropsychopharmacology, vol. 33, no. 9, pp. 2048-2060, 2008.
28. J. A. Gray and B. L. Roth, "The pipeline and future of drug development in schizophrenia, " Molecular Psychiatry, vol. 12, no. 10, pp. 904-922, 2007.
29. J. A. Gray and B. L. Roth, "Molecular targets for treating cognitive dysfunction in schizophrenia, " Schizophrenia Bulletin, vol. 33, no. 5, pp. 1100-1119, 2007.
30. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine, " Archives of General Psychiatry, vol. 45, no. 9, pp. 789-796, 1988.
31. H. Y. Meltzer, L. Alphs, A. I. Green et al., "Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT), " Archives of General Psychiatry, vol. 60, no. 1, pp. 82-91, 2003.
32. J. Brea, M. Castro, M. I. Loza et al., "QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine, " Neuropharmacology, vol. 51, no. 2, pp. 251-262, 2006.
33. A. Anighoro and G. Rastelli, "Enrichment factor analyses on G-protein coupled receptors with known crystal structure, " Journal of Chemical Information andModeling, vol. 53, no. 4, pp. 739-743, 2013.
34. E. Gregori-Puigjané and J. Mestres, "A ligand-based approach to mining the chemogenomic space of drugs, " Combinatorial Chemistry & HighThroughput Screening, vol. 11, no. 8, pp. 669-676, 2008.
35. B. Selvam, S. L. Porter, and I. G. Tikhonova, "Addressing selective polypharmacology of antipsychotic drugs targeting the bioaminergic receptors through receptor dynamic conformational ensembles, " Journal of Chemical Information and Modeling, vol. 53, no. 7, pp. 1761-1774, 2013.
36. I. Vogt and J. Mestres, "Drug-target networks, " Molecular Informatics, vol. 29, no. 1-2, pp. 10-14, 2010.
37. B. L. Roth and D.-M. Chuang, "Multiple mechanisms of serotonergic signal transduction, " Life Sciences, vol. 41, no. 9, pp. 1051-1064, 1987.
38. J. D. Urban, W. P. Clarke, M. von Zastrow et al., "Functional selectivity and classical concepts of quantitative pharmacology, " Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 1, pp. 1-13, 2007.
39. J. D. Urban, G. A. Vargas, M. von Zastrow, and R. B. Mailman, "Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways, " Neuropsychopharmacology, vol. 32, no. 1, pp. 67-77, 2007.
40. J. Jin, B. L. Roth, and S. Frye, "Novel Functionally Selective Ligands of Dopamine D2 Receptors, " US Patent 20, 130, 137, 679, 2013.
41. J. A. Allen, J. M. Yost, V. Setola et al., "Discovery of -arrestinbiased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 45, pp. 18488-18493, 2011.
42. X. Chen, M. F. Sassano, L. Zheng et al., "Structure-functional selectivity relationship studies of -arrestin-biased dopamine D2 receptor agonists, " Journal of Medicinal Chemistry, vol. 55, no. 16, pp. 7141-7153, 2012.
43. J. A. Allen and B. L. Roth, "Strategies to discover unexpected targets for drugs active at G protein-coupled receptors, " Annual Review of Pharmacology and Toxicology, vol. 51, pp. 117-144, 2011.
44. R. B. Mailman, "GPCR functional selectivity has therapeutic impact, " Trends in Pharmacological Sciences, vol. 28, no. 8, pp. 390-396, 2007.
45. P. Coward, S. D. Chan, H. G. Wada, G. M. Humphries, and B. R. Conklin, "Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors, " Analytical Biochemistry, vol. 270, no. 2, pp. 242-248, 1999.
46. E. Kostenis, M. Waelbroeck, and G. Milligan, "Techniques: promiscuous G proteins in basic research and drug discovery, " Trends in Pharmacological Sciences, vol. 26, no. 11, pp. 595-602, 2005.
47. T. P. Kenakin, "Ligand detection in the allosteric world, " Journal of Biomolecular Screening, vol. 15, no. 2, pp. 119-130, 2010.
48. L. T. May, K. Leach, P. M. Sexton, and A. Christopoulos, "Allostericmodulation of G protein-coupled receptors, " Annual Review of Pharmacology and Toxicology, vol. 47, pp. 1-51, 2007.
49. J. A. Lewis, E. P. Lebois, and C. W. Lindsley, "Allosteric modulation of kinases and GPCRs: design principles and structural diversity, " Current Opinion in Chemical Biology, vol. 12, no. 3, pp. 269-280, 2008.
50. Z. Fang, C. Grütter, and D. Rauh, "Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features, " ACS Chemical Biology, vol. 8, no. 1, pp. 58-70, 2013.
51. B. J. Melancon, C. R. Hopkins, M. R. Wood et al., "Allosteric modulation of seven transmembrane spanning receptors: Theory, practice, and opportunities for central nervous systemdrug discovery, " Journal of Medicinal Chemistry, vol. 55, no. 4, pp. 1445-1464, 2012.
52. A. Anighoro, J. Bajorath, and G. Rastelli, "Polypharmacology: challenges and opportunities in drug discovery, " Journal of Medicinal Chemistry, vol. 57, no. 19, pp. 7874-7887, 2014.
53. T. Arya, C. Kishor, V. Saddanapu, R. Reddi, and A. Addlagatta, "Discovery of a new genetic variant of methionine aminopeptidase from Streptococci with possible post-translational modifications: biochemical and structural characterization, " PLoS ONE, vol. 8, no. 10, Article IDe75207, 2013.
54. R. Nisticò, C. Ferraina, V. Marconi et al., "Age-related changes of protein SUMOylation balance in the APP Tg2576 mouse model of Alzheimer's disease, " Frontiers in Pharmacology, vol. 5, article 63, 2014.
55. A. S. Bassett, S. W. Scherer, and L. M. Brzustowicz, "Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease, " The American Journal of Psychiatry, vol. 167, no. 8, pp. 899-914, 2010.
56. H. M. Grayton, C. Fernandes, D. Rujescu, and D. A. Collier, "Copy number variations in neurodevelopmental disorders, " Progress in Neurobiology, vol. 99, no. 1, pp. 81-91, 2012.
57. C. N. Henrichsen, E. Chaignat, and A. Reymond, "Copynumber variants, diseases and gene expression, " Human Molecular Genetics, vol. 18, no. 1, pp. R1-R8, 2009.
58. E. H. Cook Jr. And S. W. Scherer, "Copy-number variations associated with neuropsychiatric conditions, " Nature, vol. 455, no. 7215, pp. 919-923, 2008.
59. Z. Liu, J. Zhang, and A. Zhang, "Design of multivalent ligand targeting G-protein-coupled receptors, " Current Pharmaceutical Design, vol. 15, no. 6, pp. 682-718, 2009.
60. R. Morphy and Z. Rankovic, "Designed multiple ligands. An emerging drug discovery paradigm, " Journal of Medicinal Chemistry, vol. 48, no. 21, pp. 6523-6543, 2005.
61. C. P. Adams andV. V. Brantner, "Estimating the cost of new drug development: is it really 802million dollars?" Health Affairs, vol. 25, no. 2, pp. 420-428, 2006.
62. I. M. Kapetanovic, "Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach, " Chemico-Biological Interactions, vol. 171, no. 2, pp. 165-176, 2008.
63. M. Pirmohamed, S. James, S. Meakin et al., "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, " BritishMedical Journal, vol. 329, no. 7456, pp. 15-19, 2004.
64. R. Shankar, X. Frapaise, and B. Brown, "LEAN drug development in R&D, " Drug Discovery & Development, vol. 9, no. 5, pp. 57-60, 2006.
65. A. Rowan, Of Mice, Models and Men: A Critical Evaluation of Animal Research, State University of New York Press, Albany, NY, USA, 1984.
66. T. N. Raju, "The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98), " The Lancet, vol. 355, no. 9208, p. 1022, 2000.
67. A. L. Hopkins, J. S. Mason, and J. P. Overington, "Can we rationally design promiscuous drugs?" Current Opinion in Structural Biology, vol. 16, no. 1, pp. 127-136, 2006.
68. I. Nobeli, A. D. Favia, and J. M. Thornton, "Protein promiscuity and its implications for biotechnology, " Nature Biotechnology, vol. 27, no. 2, pp. 157-167, 2009.
69. J.-U. Peters, P. Schnider, P. Mattei, and M. Kansy, "Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds, " ChemMedChem, vol. 4, no. 4, pp. 680-686, 2009.
70. A. Merino, A. K. Bronowska, D. B. Jackson, and D. J. Cahill, "Drug profiling: knowing where it hits, " Drug Discovery Today, vol. 15, no. 17-18, pp. 749-756, 2010.
71. A. S. Reddy and S. Zhang, "Polypharmacology: drug discovery for the future, " Expert Review of Clinical Pharmacology, vol. 6, no. 1, pp. 41-47, 2013.
72. Z. Simon, A. Peragovics, M. Vigh-Smeller et al., "Drug effect prediction by polypharmacology-based interaction profiling, " Journal of Chemical Information andModeling, vol. 52, no. 1, pp. 134-145, 2012.
73. M. A. Yildirim, K.-I. Goh, M. E. Cusick, A.-L. Barabási, and M. Vidal, "Drug-target network, " Nature Biotechnology, vol. 25, no. 10, pp. 1119-1126, 2007.
74. B. M. Padhy and Y. K. Gupta, "Drug repositioning: reinvestigating existing drugs for new therapeutic indications, " Journal of PostgraduateMedicine, vol. 57, no. 2, pp. 153-160, 2011.
75. G. Jin and S. T. C. Wong, "Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines, " Drug Discovery Today, vol. 19, no. 5, pp. 637-644, 2014.
76. B. N. Armbruster and B. L. Roth, "Mining the receptorome, "The Journal of Biological Chemistry, vol. 280, no. 7, pp. 5129-5132, 2005.
77. N. H. Jensen and B. L. Roth, "Massively parallel screening of the receptorome, "Combinatorial Chemistry&HighThroughput Screening, vol. 11, no. 6, pp. 420-426, 2008.
78. B. L. Roth, "Receptor systems: will mining the receptorome yield novel targets for pharmacotherapy?" Pharmacology & Therapeutics, vol. 108, no. 1, pp. 59-64, 2005.
79. B. L. Roth and W. K. Kroeze, "Screening the receptorome yields validated molecular targets for drug discovery, " Current Pharmaceutical Design, vol. 12, no. 14, pp. 1785-1795, 2006.
80. B. L. Roth, D. J. Sheffer, and W. K. Kroeze, "Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia, " Nature Reviews Drug Discovery, vol. 3, no. 4, pp. 353-359, 2004.
81. R. T. Strachan, G. Ferrara, and B. L. Roth, "Screening the receptorome: An efficient approach for drug discovery and target validation, " Drug Discovery Today, vol. 11, no. 15-16, pp. 708-716, 2006.
82. B. L. Roth, E. Lopez, S. Beischel, R. B. Westkaemper, and J. M. Evans, "Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: A novel approach for CNS drug discovery, " Pharmacology &Therapeutics, vol. 102, no. 2, pp. 99-110, 2004.
83. B. L. Roth, E. Lopez, S. Patel, and W. K. Kroeze, "The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?" Neuroscientist, vol. 6, no. 4, pp. 252-262, 2000.
84. J. A. Ballesteros, L. Shi, and J. A. Javitch, "Structural mimicry in G protein-coupled receptors: Implications of the highresolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors, " Molecular Pharmacology, vol. 60, no. 1, pp. 1-19, 2001.
85. D. A. Shapiro, K. Kristiansen, D. M. Weiner, W. K. Kroeze, and B. L. Roth, "Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6, " Journal of Biological Chemistry, vol. 277, no. 13, pp. 11441-11449, 2002.
86. G. Fenalti, P. M. Giguere, V. Katritch et al., "Molecular control of -opioid receptor signalling, " Nature, vol. 506, no. 7487, pp. 191-196, 2014.
87. E. Vardy, P. D. Mosier, K. J. Frankowski et al., "Chemotypeselective modes of action of -opioid receptor agonists, " The Journal of Biological Chemistry, vol. 288, no. 48, pp. 34470-34483, 2013.
88. C. Wang, Y. Jiang, J. Ma et al., "Structural basis for molecular recognition at serotonin receptors, " Science, vol. 340, no. 6132, pp. 610-614, 2013.
89. C. Wang, H. Wu, T. Evron et al., "Structural basis for Smoothened receptormodulation and chemoresistance to anticancer drugs, "Nature Communications, vol. 5, article4355, 2014.
90. C. Wang, H. Wu, V. Katritch et al., "Structure of the human smoothened receptor bound to an antitumour agent, " Nature, vol. 497, no. 7449, pp. 338-343, 2013.
91. H. Wu, D. Wacker, M. Mileni et al., "Structure of the human -opioid receptor in complex with JDTic, " Nature, vol. 485, no. 7398, pp. 327-332, 2012.
92. J. D. Hutcheson, V. Setola, B. L. Roth, and W. D. Merryman, "Serotonin receptors and heart valve disease-it was meant 2B, " Pharmacology &Therapeutics, vol. 132, no. 2, pp. 146-157, 2011.
93. R. B. Rothman, M. H. Baumann, J. E. Savage et al., "Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications, " Circulation, vol. 102, no. 23, pp. 2836-2841, 2000.
94. V. Setola, S. J. Hufeisen, K. J. Grande-Allen et al., "3, 4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro, "Molecular Pharmacology, vol. 63, no. 6, pp. 1223-1229, 2003.
95. V. Setola and B. L. Roth, "Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen', " Expert Opinion on Drug Metabolism & Toxicology, vol. 1, no. 3, pp. 377-387, 2005.
96. W. K. Kroeze, S. J. Hufeisen, B. A. Popadak et al., "H1-histamine receptor affinity predicts short-termweight gain for typical and atypical antipsychotic drugs, " Neuropsychopharmacology, vol. 28, no. 3, pp. 519-526, 2003.
97. B. L. Roth, K. Baner, R. Westkaemper et al., "Salvinorin A: A potent naturally occurring nonnitrogenous opioid selective agonist, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11934-11939, 2002.
98. Z. Feng, L. Chen, H. Maddula et al., "LigandDepot: A datawarehouse for ligands bound to macromolecules, " Bioinformatics, vol. 20, no. 13, pp. 2153-2155, 2004.
99. J. J. Irwin and B. K. Shoichet, "ZINC-a free database of commercially available compounds for virtual screening, " Journal of Chemical Information and Modeling, vol. 45, no. 1, pp. 177-182, 2005.
100. M. Kanehisa, S. Goto, Y. Sato, M. Furumichi, and M. Tanabe, "KEGG for integration and interpretation of large-scale molecular data sets, " Nucleic Acids Research, vol. 40, no. 1, pp. D109-D114, 2012.
101. Y. Wang, J. Xiao, T. O. Suzek et al., "PubChem's BioAssay database, " Nucleic Acids Research, vol. 40, no. 1, pp. D400-D412, 2012.
102. D. L. Wheeler, T. Barrett, D. A. Benson et al., "Database resources of the National Center for Biotechnology Information, " Nucleic Acids Research, vol. 36, no. 1, pp. D13-D21, 2008.
103. Y. Pouliot, A. P. Chiang, and A. J. Butte, "Predictingadversedrug reactions using publicly available PubChem BioAssay data, " Clinical Pharmacology and Therapeutics, vol. 90, no. 1, pp. 90-99, 2011.
104. M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, and B. K. Shoichet, "Relating protein pharmacology by ligand chemistry, " Nature Biotechnology, vol. 25, no. 2, pp. 197-206, 2007.
105. M. J. Keiser, V. Setola, J. J. Irwinet al., "Predictingnewmolecular targets for known drugs, " Nature, vol. 462, no. 7270, pp. 175-181, 2009.
106. E. Lounkine, M. J. Keiser, S. Whitebread et al., "Large-scale prediction and testing of drug activity on side-effect targets, " Nature, vol. 486, no. 7403, pp. 361-367, 2012.
107. A.-L. Barabási and Z. N. Oltvai, "Network biology: understanding the cell's functional organization, " Nature Reviews Genetics, vol. 5, no. 2, pp. 101-113, 2004.
108. M. Campillos, M. Kuhn, A.-C. Gavin, L. J. Jensen, and P. Bork, "Drug target identification using side-effect similarity, " Science, vol. 321, no. 5886, pp. 263-266, 2008.
109. J. K. Morrow, L. Tian, and S. Zhang, "Molecular networks in drug discovery, " Critical Reviews in Biomedical Engineering, vol. 38, no. 2, pp. 143-156, 2010.
110. L. Tian and S. Zhang, "Mapping drug-target interaction networks, " in Proceedings of the Annual International Conference of the IEEE Engineering inMedicine and Biology Society (EMBC '09), pp. 2336-2339, IEEE, Minneapolis, Minn, USA, September 2009.
111. A. P. Davis, B. L. King, S. Mockus et al., "The comparative toxicogenomics database: update 2011, " Nucleic Acids Research, vol. 39, no. 1, pp. D1067-D1072, 2011.
112. T. I. Oprea and J. Mestres, "Drug repurposing: far beyond new targets for old drugs, "The AAPS Journal, vol. 14, no. 4, pp. 759-763, 2012.
113. T. I. Oprea, S. Kim Nielsen, O. Ursu et al., "Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing, " Molecular Informatics, vol. 30, no. 2-3, pp. 100-111, 2011.
114. F. Cheng, Y. Zhou, W. Li, G. Liu, and Y. Tang, "Prediction of chemical-protein interactions network with weighted networkbased inference method, " PLoS ONE, vol. 7, no. 7, Article ID e41064, 2012.
115. D. Reker, T. Rodrigues, P. Schneider, and G. Schneider, "Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 11, pp. 4067-4072, 2014.
116. C. A. Erickson, J. M. Veenstra-Vanderweele, R. D. Melmed et al., "STX209 (arbaclofen) for autism spectrum disorders: An 8-week open-label study, " Journal of Autism and Developmental Disorders, vol. 44, no. 4, pp. 958-964, 2014.
117. J. R. Morphy and C. J. Harris, Designing Multi-Target Drugs, Royal Society of Chemistry, London, UK, 2012.
118. B. Apsel, J. A. Blair, B. Gonzalez et al., "Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases, " Nature Chemical Biology, vol. 4, no. 11, pp. 691-699, 2008.
119. J. Besnard, G. F. Ruda, V. Setola et al., "Automated design of ligands to polypharmacological profiles, " Nature, vol. 492, no. 7428, pp. 215-220, 2012.
120. K. D. McLaren and L. B. Marangell, "Special considerations in the treatment of patients with bipolar disorder and medical comorbidities, " Annals of General Hospital Psychiatry, vol. 3, no. 1, article 7, 2004.
121. E. M. Berry-Kravis, D. Hessl, B. Rathmell et al., "Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial, " Science Translational Medicine, vol. 4, no. 152, Article ID 152ra127, 2012.
122. A. Healy, R. Rush, and T. Ocain, "Fragile X syndrome: An update on developing treatment modalities, " ACS Chemical Neuroscience, vol. 2, no. 8, pp. 402-410, 2011.
123. R. Lozano, E. B. Hare, and R. J. Hagerman, "Modulation of the GABAergic pathway for the treatment of fragile X syndrome, " Neuropsychiatric Disease and Treatment, vol. 10, pp. 1769-1779, 2014.
124. M. R. Mohammadi, L. Kashani, S. Akhondzadeh, E. S. Izadian, and S. Ohadinia, "Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: A pilot doubleblind randomized trial, " Journal of Clinical Pharmacy and Therapeutics, vol. 29, no. 2, pp. 139-144, 2004.
125. H. J. Moller, K. Demyttenaere, B. Olausson et al., "Two phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy, " The World Journal of Biological Psychiatry, vol. 16, no. 7, pp. 483-501, 2015.
126. E. Vieta, M. E. Thase, D. Naber et al., "Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant, " European Neuropsychopharmacology, vol. 24, no. 4, pp. 564-574, 2014.
127. A. Corbett, J. Smith, and C. Ballard, "New and emerging treatments for Alzheimers disease, " Expert Review of Neurotherapeutics, vol. 12, no. 5, pp. 535-543, 2012.
128. T. P. George, K. A. Sacco, J. C. Vessicchio, A. H. Weinberger, and R. D. Shytle, "Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractorymajor depressive disorder: A preliminary study, " Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 340-344, 2008.
129. E. D. Levin and B. B. Simon, "Nicotinic acetylcholine involvement in cognitive function in animals, " Psychopharmacology, vol. 138, no. 3-4, pp. 217-230, 1998.
130. A. Singh, D. K. Das, and M. E. Kelley, "Mecamylamine: Targacept, " IDrugs, vol. 9, no. 3, pp. 205-217, 2006.
131. K.-I. Ueno, H. Togashi, M. Matsumoto, S. Ohashi, H. Saito, and M. Yoshioka, "42 Nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, " The Journal of Pharmacology and ExperimentalTherapeutics, vol. 302, no. 1, pp. 95-100, 2002.
132. J. K. Belanoff, B. H. Flores, M. Kalezhan, B. Sund, and A. F. Schatzberg, "Rapid reversal of psychotic depression using mifepristone, " Journal of Clinical Psychopharmacology, vol. 21, no. 5, pp. 516-521, 2001.
133. C. M. Blasey, T. S. Block, J. K. Belanoff, and R. L. Roe, "Efficacy and safety of mifepristone for the treatment of psychotic depression, " Journal of Clinical Psychopharmacology, vol. 31, no. 4, pp. 436-440, 2011.
134. B. J. Carroll and R. T. Rubin, "Mifepristone in psychotic depression?" Biological Psychiatry, vol. 63, no. 1, pp. e1-e3, 2008.
135. R. H. Howland, "Mifepristone as a therapeutic agent in psychiatry, " Journal of Psychosocial Nursing andMental Health Services, vol. 51, no. 6, pp. 11-14, 2013.
136. C. E. Clarke andK. H. Deane, "Ropinirole for levodopa-induced complications in Parkinson's disease, " The Cochrane Database of Systematic Reviews, vol. 3, Article IDCD001516, 2000.
137. C. E. Clarke andK. H. Deane, "Ropinirole for levodopa-induced complications in Parkinson's disease, " The Cochrane Database of Systematic Reviews, no. 1, Article ID CD001516, 2001.
138. R. Tomasiuk, S. Szlufik, A. Friedman, and D. Koziorowski, "Ropinirole treatment in Parkinson's disease associated with higher serum level of inflammatory biomarker NT-proCNP, " Neuroscience Letters, vol. 566, pp. 147-150, 2014.
139. A. Yildiz, S. Guleryuz, D. P. Ankerst, D. Öngür, and P. F. Renshaw, "Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen, " Archives of General Psychiatry, vol. 65, no. 3, pp. 255-263, 2008.
140. A. Corbett, G. Williams, and C. Ballard, "Drug repositioning: An opportunity to develop novel treatments for Alzheimer's disease, " Pharmaceuticals, vol. 6, no. 10, pp. 1304-1321, 2013.